Dr. Kruse brings expertise in the structure, function, and pharmacology of transmembrane signaling proteins with essential roles in human health and disease. He determined molecular structures of two distinct acetylcholine receptors and pioneered the use of in silico docking for the development of G protein-coupled receptor (GPCR) subtype-selective modulators. In other work, he determined the molecular basis for allosteric modulation of GPCR signaling by drug-like small molecules, paving the way for the use of crystal structures in the development of this emerging class of therapeutics. Dr. Kruse’s work has been published in more than thirty peer-reviewed papers. Dr. Kruse holds bachelor’s degrees in Biochemistry and Mathematics from the University of Minnesota, and a Ph.D. in Structural Biology from Stanford University. Following completion of his doctoral work he was recruited to Harvard Medical School, where he serves as an Assistant Professor of Biological Chemistry and Molecular Pharmacology. He has received awards including a National Science Foundation Graduate Research Fellowship, an NIH Director’s Early Independence Award, and a Smith Family Foundation Award for Excellence in Biomedical Research. He was selected as a member of the 2016 Forbes 30 under 30 list in Healthcare.

Healthcare, Business of Healthcare, Harvard, Stanford University, Co-founder, Entrepreneurship, Science, Biologists, Physicists, Biology